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Vascular endothelial growth factor activates MAP kinase and as wound healing after skin wounds and after myocardial
enhances collagen synthesis in human mesangial cells. infarction, as well as in other conditions such as rheuma-
Background. Vascular endothelial growth factor (VEGF) is toid arthritis and inflammatory skin disorders. Part of
an endothelial mitogen that is constitutively expressed in nor-
the interest in this cytokine is due to the fact that VEGFmal human glomeruli, but its role in the kidney is still unclear.
is thought to be unique among the growth factors inIn this study, we examined the effects of VEGF on human
mesangial cells (HMCs). being essentially endothelial cell specific in its actions,
Methods and Results. Reverse transcription-polymerase with few effects outside the vascular endothelium [1].
chain reaction analysis demonstrated the presence of VEGF In the human kidney, VEGF is known to be abun-
receptor mRNA (flt-1 and KDR) in HMCs. The treatment of dantly expressed in the podocytes of the visceral epithe-HMCs with VEGF did not cause a change in 3H-thymidine
lial cells of the glomeruli. However, the precise role ofincorporation or cell numbers. In contrast, VEGF caused a
VEGF in the kidney is still an enigma. Renal biopsydose- and time-dependent increase in collagen synthesis, with
threefold to fivefold increases in both cell-associated and se- studies that examined the localization of the receptors
creted collagen synthesis seen after treatment with 200 ng/ml for VEGF, namely flt-1 (fms-like tyrosine kinase) and
VEGF. The effects of VEGF were attenuated by treatment of KDR (kinase insert domain-containing receptor), found
HMCs with the tyrosine kinase inhibitor herbimycin A or the
them to be expressed predominantly on glomerular en-MEK inhibitor PD 98059, but not with the protein kinase C
dothelial cells, with only faint staining in the mesangial(PKC) inhibitor chelerythrine. VEGF treatment also caused a
area [3–5]. These results suggested the hypothesis thatmarked increase in p42/p44 mitogen-activated protein kinase
(MAPK) activity, but had no significant effect on HMC super- VEGF may play an important role in controlling endo-
oxide production. Finally, an increase in collagen synthesis was thelial development and postinjury regeneration in the
also seen in rat mesangial cells treated with VEGF. renal glomeruli, as well as having a potential role in
Conclusions. These results suggest that VEGF is not a mito-
enhancing endothelial permeability in conditions suchgenic signal in HMCs, but may be involved in the regulation
as the nephrotic syndrome. Several studies have beenof the mesangial matrix in humans by a MAPK-dependent
performed to try to confirm these potential actions ofmechanism.
VEGF on the endothelium. In a recent study, rat kidneys
were infused with VEGF, but no change in protein excre-
tion by the kidneys was detected [6]. Also, a study ofVascular endothelial growth factor (VEGF), also known
renal biopsies revealed that expression of VEGF in hu-as vascular permeability factor (VPF) or vasculotropin
man diseases did not always correlate with conditions of(VAS), is known to be an endothelial cell mitogen and
endothelial proliferation [7]. Therefore, the physiologi-stimulator of angiogenesis [1, 2]. It is also a potent en-
cal or pathological role of VEGF in glomerular endothe-hancer of microvascular permeability. Much attention
lial cells has not yet been clearly defined.has been centered on the potential role of VEGF in
Recently, expression of both receptors for VEGF (flt-1the angiogenesis of malignant tumors and also in the
and KDR) has been demonstrated in rat mesangial cellsangiogenesis accompanying non-neoplastic diseases such
[8, 9]. In one of these articles, the authors examined
whether the classic endothelial actions of VEGF, that
Key words: mitogen activated protein kinase, VEGF, mesangial matrix, is, to cause cell proliferation and/or regulate nitric oxide
angiogenesis, injury. production, could be seen in mesangial cells. Because no
effect of VEGF on mesangial cells could be demonstrated,Received for publication December 22, 1998
the authors concluded that VEGF may not be involved inand in revised form July 14, 1999
Accepted for publication August 3, 1999 the pathogenesis of mesangial cell structural or functional
pathology in disease states such as diabetic nephropathy [9]. 1999 by the International Society of Nephrology
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In our study, we reasoned that although mesangial cells Analysis of vascular endothelial growth factor
receptor phosphorylationare a nonendothelial tissue, the presence of VEGF recep-
tors on HMCs suggests that some (non-mitogenic) action Vascular endothelial growth factor receptor phosphory-
of VEGF on the mesangium cannot be ruled out. Because lation was examined as described by Seetharam et al [13],
mesangial cells are an important regulator of the mesan- with minor modifications. In brief, HMCs were made
gial matrix, we focused on the effects of VEGF on colla- quiescent by placing them in serum-free CCMD 180 for
gen synthesis in human mesangial cells (HMCs) and ex- 48 hours. The cells were treated with VEGF (200 ng/ml)
amined the intracellular signals involved in these changes. for the times indicated, and then reactions were termi-
nated by rinsing with ice-cold phosphate-buffered saline
(PBS), followed by lysis in immunoprecipitation bufferMETHODS
[50 mm HEPES, 150 mm NaCl, 1% Triton X-100, 1.5 mm
Culture of human mesangial cells and rat mesangial cells MgCl2, 1 mm ethyleneglycoltetraacetic acid (EGTA),
Human mesangial cells were obtained from Clonetics 1 mm phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml leu-
peptin, 50 mm sodium fluoride, 10 mm sodium pyrophos-(Tokyo, Japan) and were cultured in CCMD 180 medium
phate, 5 mm ethylenediaminetetraacetic acid (EDTA),supplemented with 5% fetal calf serum (FCS), and the
and 2 mm sodium orthovanadate]. The lysates were firstantibiotics gentamycin and amphotericin. Experiments
precleared with Pansorbin, and then the protein concen-were performed on early (#6) passage cells. Rat mesan-
trations were determined by the modified Lowry methodgial cells from Sprague-Dawley rats were obtained by
[14]. Lysates containing equal amounts of protein (200 mg)enzymatic digestion, as described previously [10], and
were incubated with affinity-purified polyclonal anti-flt 1were cultured in RPMI 1640 supplemented with 10% FCS.
or anti-KDR antibodies (1:100; Santa Cruz, Santa Cruz,
Isolation of total RNA and reverse CA, USA) at 48C for two hours. The resulting immune
transcription-polymerase chain reaction complexes were collected by precipitation with Pansor-
of flt-1 and KDR mRNA bin, washed three times with immunoprecipitation buffer,
resuspended in 1 3 Laemmli electrophoresis buffer, andTotal RNA was purified from HMCs by the acid guani-
heated at 958C for five minutes. Proteins were resolveddine-phenol-chloroform method [11] and was quanti-
by electrophoresis on 10% sodium dodecyl sulfate-poly-tated by measurement of absorbance at 260 nm in a
acrylamide gel electrophoresis (SDS-PAGE) gels andspectrophotometer. Total RNA (1 mg) was subjected
transferred to nitrocellulose membranes. Tyrosine phos-to reverse transcription-polymerase chain reaction (RT-
phorylation of the receptors was visualized by WesternPCR) using primers specific for flt-1 and KDR/flk [12].
blotting of the membranes with monoclonal antiphospho-In brief, 1 mg total RNA was reverse transcribed in a
tyrosine antibody (Santa Cruz PY99, 1:200) and horse-reaction mixture containing 10 mm Tris HCl (pH 8.3),
radish peroxidase-coupled secondary antibody, using the50 mm KCl, 5 mm MgCl2, 1 mm dNTP, 1 U RNase inhibitor, enhanced chemiluminescence (ECL) detection system2.5 mm (50 pmol) random hexamers, and 2.5 U Moloney
(Amersham, Arlington Heights, IL, USA). The relativemurine leukemia virus reverse transcriptase in a volume
intensities of the bands were assessed using computer
of 20 ml. After incubation at room temperature for 10
densitometry software (Scion Image).
minutes and 428C for 30 minutes, the samples were heated
for five minutes at 958C to terminate the reactions. The Determination of cell proliferation
RT products were amplified with flt-1 or KDR sense and Human mesangial cells in 24-well plates were made
antisense primers in a reaction mixture containing 10 mm quiescent by placing them for 48 hours in Dulbecco’s
Tris HCl (pH 8.3), 50 mm KCl, 2 mm MgCl2, 0.2 mm modified Eagle’s medium (DMEM) containing selenium
dNTP, 15 pmol of each primer, and 2.5 U Taq polymerase (6.7 ng/ml), insulin (10 mg/ml), and transferrin (5.5 mg/ml).
using a Perkin-Elmer-Cetus thermal cycler. The amplifi- The cells were treated with VEGF (200 ng/ml), angioten-
cation profile consisted of denaturation at 958C for 30 sin II (Ang II; 1026 m), or FCS (5%) for 48 hours, and
seconds, annealing at 548C for 60 seconds, and extension cell counts were determined with a cytometer. In parallel
at 728C for 90 seconds for 35 cycles. The flt-1 sense and experiments, cells were treated in a similar manner, and
antisense primers were as follows: 59GTGGAAG then thymidine incorporation was determined by pulsing
AAATGGCAAACAA-39 and 59-ACAGGTCAGAA them with 3H-thymidine (1 mCi/ml) for the final 24 hours.
GCCCTATTT-39. The KDR primers were 59-GAAAT After removing the medium, the cells were washed with
GACACTGGAGCCTAC-39 and 59-TTCCCAGTTGA PBS and incubated with 10% trichloroacetic acid (TCA)
AGTCAATCC-39. The flt-1 and KDR product sizes at 48C for 30 minutes. The cellular precipitate was solubi-
were 380 and 500 bp, respectively. Reaction products lized in 0.1 m NaOH, 0.5% SDS, and the incorporated
were subjected to agarose gel electrophoresis, and bands thymidine was determined by liquid scintillation spec-
trometry.were visualized by staining with ethidium bromide.
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Determination of collagen synthesis of the supernatant to 15 ml of substrate peptide mix in
the presence of [g-32P]ATP. After termination of theSynthesis of cell-associated and secreted collagen was
reactions with orthophosphoric acid, the samples weredetermined as described previously with minor modifi-
spotted onto phosphocellulose filters and washed withcations [15, 16]. In brief, quiescent HMCs in 24-well
acetic acid and H2O, and then the radioactivity was deter-plates were stimulated with VEGF (200 ng/ml, unless oth-
mined by scintillation counting. In a separate series oferwise stated) in the presence of ascorbic acid (50 mg/ml)
experiments, lysates containing 20 mg protein were sub-for the indicated times. 3H-proline (4 mCi/ml) was added
jected to immunoprecipitation at 48C for two hours withduring the last 24 hours of stimulation. After removing
affinity-purified rabbit antihuman p42/p44 MAPK IgGthe medium, the cells were rinsed and then incubated
(1:50; Calbiochem, La Jolla, CA, USA). Immune com-with 10% TCA at 48C for 30 minutes. The cellular precip-
plexes were collected with Pansorbin, washed three timesitate was solubilized in 0.1 m NaOH and then neutralized
in lysis buffer, and resuspended in MAPK assay buffer
to a final concentration of 50 mm HEPES (pH 7.4), 2.5 prior to the assay of MAPK activity. All experiments
mm CaCl2, and incubated with bacterial collagenase type were performed within the linear range of the assay
III (final concentration 100 U/ml) overnight at room (incorporated counts ,10% of total count), as specified
temperature. Following protein precipitation with ice- by the manufacturers.
cold TCA, samples were solubilized for scintillation
counting, and de novo collagen synthesis was determined Superoxide production
from the collagenase-sensitive proline incorporation. To Superoxide production by HMCs was measured as
estimate newly synthesized collagen in media proteins, the superoxide dismutase (SOD)-inhibitable reduction of
aliquots of the media were incubated with collagenase ferricytochrome c as described previously [17, 18]. Briefly,
overnight at room temperature. Media proteins were HMCs were incubated in DMEM without phenol red
precipitated by the addition of 1/10 volume of ice-cold for 30 minutes at 378C, and then with cytochrome c (final
100% TCA, and collagen synthesis was determined in concentration 1 mg/ml) with or without SOD (final con-
the same manner. centration 500 U/ml), and the mixture was kept in a CO2
incubator. At the indicated times, the medium was re-
Enzyme immunoassay for procollagen type 1 C-peptide moved from the cells, and the absorbance was read at 550
Procollagen type 1 C-peptide (PICP) concentrations nm against a distilled water blank. The optical difference
between comparable wells with or without SOD waswere measured using two-step enzyme immunoassay
converted to equivalent superoxide production by using(EIA). After coating enzyme-linked immunosorbent
the molar extinction coefficient for cytochrome c [2110assay (ELISA) wells with anti-PICP antibody (Takara,
mm21(mol/liter)21].Shiga, Japan) overnight at 48C, the wells were rinsed
and then incubated with blocking agent at 378C for two
Statisticshours. Next, samples were added and incubated for one
Results are expressed as the mean 6 sem. Statisticalhour, followed by the addition of labeled secondary anti-
comparisons were made by analysis of variance followedbody. After an addition of the substrate o-phenylenedia-
by Scheffe’s F-test. P values of less than 0.05 were consid-mine-HCl, the absorbance was measured at 490 nm, and
ered statistically significant.concentrations were calculated by comparison to known
standards. The intra-assay and interassay coefficients of Materials
this assay are 5.4 and 6.6%, respectively (N 5 16).
Human recombinant VEGF (165 amino acid form;
molecular weight 42 kDa; purity .97%) was obtainedMitogen-activated protein kinase assay
from Sigma (St. Louis, MO, USA). Cell culture materi-
Mitogen-activated protein kinase (MAPK) activity als, radioisotopes, and electrophoresis materials were
was assessed using the p42/p44 MAPK enzyme assay obtained from GIBCO-BRL (Grand Island, NY, USA),
system (Amersham), which contains a synthetic peptide Amersham International, and Bio-Rad (Hercules, CA,
substrate for p42/p44 MAPK. Quiescent HMCs in 24- USA), respectively. Other reagents were obtained from
well plates were stimulated with VEGF for the indicated Sigma, unless otherwise stated.
times. The cells were then rinsed in ice-cold PBS, and
the reactions were terminated by the addition of ice-cold
RESULTSlysis buffer (10 mm Tris, pH 7.4, 150 mm NaCl, 2 mm
Analysis of VEGF receptor mRNA andEGTA, 1 mm sodium orthovanadate, 1 mm PMSF, 10
VEGF-induced receptor tyrosinemg/ml aprotinin, and 500 mm dithiothreitol). The cells
phosphorylation in HMCwere homogenized with a Polytron homogenizer and
then centrifuged (25,000 g for 20 min at 48C). MAPK Expression of the mRNA for human flt-1 and KDR
was examined by RT-PCR using total RNA derived fromreaction assays were initiated by the addition of 15 ml
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Fig. 1. (A) Analysis of flt-1 and KDR mRNA
in human mesangial cells (HMC) by reverse
transcription-polymerase chain reaction (RT-
PCR). One microgram of total RNA from
HMC was subjected to RT-PCR using flt-1
or KDR specific primers, as described in the
Methods section. The location of the bands
of the expected sizes (flt-1380 bp, KDR 500
bp) is shown by arrows. (B and C) Analysis
of VEGF receptor phosphorylation in HMCs.
HMCs were stimulated for the indicated times
with VEGF (200 ng/ml), and then cell lysates
were prepared and immunoprecipitated using
(B) anti-flt-1 or (C) anti-KDR antibodies as
described in the Methods section. The immu-
noprecipitates were subjected to SDS-PAGE
followed by immunoblotting using antiphos-
photyrosine antibodies.
HMCs, as described previously [12]. As shown in Figure teins are shown in Figure 2C. In contrast to its effects on
cell proliferation, VEGF was found to cause a significant1A, signals for both flt-1 and KDR mRNA of the ex-
pected sizes (380 and 500 bp) could be detected by agarose increase in collagen synthesis in HMCs. A smaller (1.6-
fold) but statistically significant change was seen for col-gel electrophoresis. No signals were detected in the ab-
sence of RT. Next, experiments were performed to see lagenase-insensitive protein synthesis. Similar changes
were seen in the Ang II-treated group, but the differ-if VEGF caused tyrosine phosphorylation of these recep-
ences did not reach statistical significance. The dose de-tors in HMCs. As shown in Figure 1 B and C, these experi-
pendency and time course of the VEGF effect werements confirmed that VEGF treatment resulted in a rapid
examined. As shown in Figure 3, approximately three-tyrosine phosphorylation of immunoprecipitated flt-1 and
fold to fivefold increases in cell-associated and secretedKDR receptors from HMCs. The VEGF-induced tyro-
collagen synthesis were seen after treatment with 200sine phosphorylation appeared to be attenuated in the
ng/ml VEGF for 72 hours.cells that had been pretreated with herbimycin A (1 mm).
The effects of VEGF and FCS on steady-state concen-
Effects of VEGF on proliferation of HMC trations of PICP, a readily quantifiable fragment of type
1 collagen, were examined by EIA, and the results areThe effects of VEGF on HMC proliferation, as as-
presented in Table 1. The pattern of the effects of VEGFsessed by cell counts and thymidine incorporation, are
on PICP was similar to the effects on proline incorpora-shown in Figure 2 A and B. No significant changes in
tion, although the magnitude of the detected changes waseither cell counts or thymidine incorporation were seen
smaller. These results were considered to be compatiblein cells treated with VEGF. Results for the control mito-
with the assumption that collagen proteins have a rela-genic signal FCS and the nonmitogenic agonist Ang II,
tively low turnover; therefore, changes in de novo colla-which were run in parallel, are also shown for compari-
gen synthesis may not have such a large impact on theson. A significant increase in cell count together with a
total pool of collagens. Thus, FCS caused a significantrobust increase in thymidine incorporation was seen in
increase in PICP concentrations, with VEGF causingthe FCS-treated cells.
a similar but lesser effect that did not reach statistical
Effects of VEGF on collagen synthesis in HMC significance. The effects of VEGF and FCS on type IV
collagen concentrations were also examined, but the con-The effects of the same agents on collagenase-sensitive
and -insensitive proline incorporation into cellular pro- centrations were below the limit of assay reliability.
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Fig. 2. Effects of vascular endothelial growth
factor (VEGF) on human mesangial cell (HMC)
proliferation and collagen synthesis. Quies-
cent HMCs were treated for 48 hours with
VEGF (200 ng/ml), angiotensin II (Ang II;
1026 m), or fetal calf serum (FCS; 5%). (A)
Cell number, (B) thymidine incorporation,
and (C) collagen (h) and noncollagen ( )
protein synthesis were assayed as described
in the Methods section. Results shown are the
mean 6 sem (N shown in parentheses). *P ,
0.05; **P , 0.01 vs. control.
Fig. 3. (A) Dose-dependency and (B) time
course of of vascular endothelial growth factor
(VEGF)-induced increases in cell-associated
(h) and secreted ( ) collagen synthesis in
human mesangial cells (HMCs). Quiescent
HMCs were treated with (A) various doses of
VEGF for 48 hours or (B) with 200 ng/ml
VEGF for various times, and then collagen
synthesis was assayed as described in the
Methods section. Results shown are the mean
6 sem (N 5 4 per assay point). *P , 0.05;
**P , 0.01 vs. control.
Analysis of intracellular signals involved in p42/p44 MAPK antibody prior to the kinase reaction in
VEGF-induced collagen synthesis a separate experiment, a significant increase in activity
was also seen [VEGF 0 min 849 6 382 cpm/mg protein,The effects of pretreatment of cells with the MAPK
10 min 2404 6 314* cpm/mg protein, 15 min 1941 6 129*kinase (MEK) inhibitor PD 98059, the tyrosine kinase
cpm/mg protein (*P , 0.05 vs. time 0, N 5 4)], confirminginhibitor herbimycin A, and the protein kinase C (PKC)
that p42/p44 MAPK (ERK 1/2)-specific activity was in-inhibitor chelerythrine on VEGF-induced increases in
deed increased after VEGF stimulation.collagen synthesis in HMCs were examined. As shown
in Figure 4, the VEGF-induced increase in collagen syn-
Effects of VEGF on superoxide production in HMCthesis was significantly attenuated by PD 98059 and her-
The effects of VEGF on superoxide production werebimycin A, but not by chelerythrine, suggesting the
also examined in HMCs. In contrast to the marked effectinvolvement of tyrosine kinase and MAPK-dependent
on MAPK, no difference in superoxide production couldpathways in the VEGF-induced effects.
be detected between cells treated with VEGF compared
Effects of protein kinase C on p42/p44 MAPK activity with untreated cells (Fig. 5B).
in HMC
Effects of VEGF on collagen synthesis in ratTo examine the possibility that VEGF-induced effects
mesangial cellsare mediated by MAPK, the activity of p42/p44 MAPK
To confirm the effects of VEGF in an independentlybefore and after VEGF treatment was examined. As
obtained cell line, rat mesangial cells were harvested andshown in Figure 5A, VEGF induced a significant increase
treated with VEGF (200 ng/ml). Similar to the resultsin MAPK activity, with a peak at 10 minutes after agonist
in HMCs, VEGF caused a significant increase in collagenstimulation, which returned to baseline after 20 minutes.
When cell lysates were immunoprecipitated with anti- synthesis in these cells, as shown in Figure 6.
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Table 1. Effects of vascular endothelial growth factor (VEGF) on
type I procollagen C-peptide (PICP) concentration in the media
PICP concentration
Treatment N ng/ml
Control 8 801620
VEGF 200 ng/ml 8 10476111
FCS 5% 8 11776116a
a P , 0.05 vs. control
DISCUSSION
Vascular endothelial growth factor is a dimeric hepa-
rin-binding glycoprotein that was originally described in
guinea pig tumor cells and later purified from human Fig. 4. Effects of mitogen-activated protein kinase kinase (MEK), tyro-
sine kinase, and protein kinase C (PKC) inhibitors on vascular endothe-cell lines. VEGF exhibits a low (18%) but significant
lial growth factor (VEGF)-induced increases in collagen synthesis inoverall sequence homology with platelet-derived growth
human mesangial cells (HMCs). Quiescent HMCs were pretreated with
factor (PDGF) and a closer (53%) homology with pla- the MEK inhibitor PD 98059 (PD, 30 mm) the tyrosine kinase inhibitor
herbimycin (herb, 1 mm) or the PKC inhibitor chelerythrine (chele, 1centa growth factor [1, 2]. Five different VEGF tran-
mm) or vehicle (DMSO) for 30 minutes and then treated for 48 hoursscripts encoding peptides of 206, 189, 145, 165, and 121
with VEGF (200 ng/ml). Collagen synthesis was assayed as described
amino acids have been described. VEGF 165 is expressed in the Methods section. The results shown are the mean 6 sem (N 5
4 per assay point). *P , 0.05 vs. control; #P , 0.05 vs. DMSO(1)predominantly in most instances and is the form used in
VEGF(1).these experiments. VEGF acts by interaction with spe-
cific receptors (flt-1 and KDR) and is known to cause
mitogenesis in endothelial cells, as well as to increase
vascular permeability by inducing endothelial fenestra- results in rat mesangial cells [9], no observable mitogenic
tions [19]. VEGF has also been reported to induce the effect was seen. This was in clear contrast to the effect
expression of interstitial collagenase in endothelial cells obtained with FCS in our cells. To further dissect the
[20]. Blocking of VEGF with antibodies in newborn mice effects of VEGF on HMCs, we examined the effects
leads to abnormal glomerulogenesis [21]. VEGF is con- of VEGF on collagen synthesis, as regulation of the
stitutively expressed in normal kidneys, with expression extracellular matrix is one of the important functions of
localized mainly to the podocytes of the renal glomeruli. mesangial cells in vivo. These experiments revealed a
Because VEGF was long thought to be an endothelial dose- and time-dependent increase in collagen synthesis
cell-specific growth factor, it has been assumed that its after VEGF treatment.
major role in the adult glomeruli lies in the regulation
Next, the pathways involved in the VEGF-induced
of glomerular endothelial function. Recent studies have
effects were examined. Several stimuli, including hightherefore focused on whether VEGF could be an impor-
glucose and PDGF, are known to exert their effects throughtant regulator of endothelial permeability, and thus in-
activation of PKC. Others act predominantly through avolved in the pathogenesis of proteinuria and the ne-
tyrosine kinase pathway. In HMCs, the observed effectsphrotic syndrome. In this study, we propose that VEGF
of VEGF were inhibited by the tyrosine kinase inhibitormay also be involved in the control of mesangial cell
herbimycin A, but not the PKC inhibitor chelerythrine.collagen synthesis and that this action involves activation
Therefore, the effects of VEGF on collagen synthesisof tyrosine kinase and p42/p44 MAP kinase pathways,
appeared to be mediated by a tyrosine kinase pathway,but does not involve PKC or modulation of superoxide
consistent with other known actions of VEGF.production.
Recently, VEGF has been reported to exert its actionsIn the first stage of this study, we examined the expres-
through activation of MAPK in some cells [24]. Intrigu-sion of VEGF receptors on HMCs. Two VEGF recep-
ingly, signaling by the same receptors in other cells ap-tors, named flt-1 and KDR, have been identified [22, 23].
pears to occur by a MAPK-independent pathway [13].Both have receptor tyrosine kinase domains that are
Therefore, in this study, we examined whether theautophosphorylated after agonist simulation. Using an
VEGF-stimulated MAPK-dependent pathway was oper-RT-PCR assay, we found evidence for expression of
ative in HMCs. By measuring changes in MAPK activityboth VEGF receptors in HMCs, similar to the results in
in HMCs, we discovered that VEGF activates p42/p44previous reports on rat mesangial cells [8, 9]. Because
MAPK in these cells. Moreover, the VEGF-induced in-VEGF is known as a mitogenic signal, we next examined
crease in collagen synthesis was inhibited by the MEKthe effects of VEGF on cell number, as well as thymidine
incorporation in HMCs. In good agreement with the inhibitor PD 98059, strongly suggesting a role for MAPK
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Fig. 5. Effects of VEGF on (A) MAPK activ-
ity (B) superoxide production in HMCs. Qui-
escent HMCs were treated with (d) or with-
out (s) VEGF (200 ng/ml) for the indicated
times, and MAPK activity and superoxide
were assayed as described in the Methods sec-
tion. Results shown are the mean 6 sem
(MAPK N 5 4; superoxide N 5 6 per assay
point). **P , 0.01 vs. VEGF(2). Error bars
are inside the symbol in some cases.
one type of cell (endothelial cells) but not in others
(mesangial cells). Further studies are required to assess
the reasons for the tissue specificity of the VEGF effects.
The results of this study open the possibility of new
interpretations as to the role of VEGF in the glomeruli.
The fact that VEGF receptors exist in mesangial cells
and can activate MAPK suggests that VEGF may act as
an intraglomerular paracrine signal from the main site
of production (glomerular epithelial cells) to targets that
include both endothelial and mesangial cells. Interest-
ingly, it has been shown that mesangial cells can alsoFig. 6. Effects of VEGF on collagen synthesis in rat mesangial cells.
produce VEGF and that this production can be regulatedQuiescent rat mesangial cells were treated with VEGF (200 ng/ml) for
48 hours, and then cell-associated collagen synthesis was assayed, as [26], raising the added possibility of an autocrine loop
described in the Methods section. Symbols are: (h) collagen; ( ) non-
within the mesangium. In fact, VEGF may be involved incollagen. Results shown are the mean 6 sem (N 5 4 per assay point).
*P , 0.05 vs. control. a network of communication involving the three cellular
components of the glomerulus. This situation may be
analogous to the situation in the liver in which VEGF
has been suggested to be a signaling molecule betweenin the observed actions of VEGF in HMCs. Of interest,
hepatocytes and sinusoidal cells [27]. Of interest, VEGFrecent studies have revealed that a novel pathway involv-
has also been reported to induce the expression of theing changes in superoxide production may be involved
metalloproteinase, interstitial collagenase, in endothelialin activation of MAPK and other signaling mechanisms
cells but not in fibroblasts [20]. Thus, both matrix synthe-in several cell types [17, 18, 25]. In this mechanism, ago-
sis and degradation may be coordinately regulated bynist-induced activation of NADH oxidase results in
VEGF through its contrasting actions on endothelialPKC-dependent production of superoxide anions, which
cells and mesangial cells.has been postulated to be involved in MAPK activation.
An important question is whether disruption of suchThe superoxide pathway may also play an important role
a network might be involved in the pathogenesis of renalin intracellular signaling by PDGF in human smooth
disease. Because many of the common causes of chronicmuscle cells through activation of the transcription factor
renal disease, such as hypertensive nephrosclerosis, dia-nuclear factor-kB [18]. Because PDGF is the growth
betic nephropathy, and many types of chronic glomerulo-factor with which VEGF shares a small but significant
nephritis syndrome are characterized by increased mes-homology [1], we asked if similar changes in superoxide
angial matrix in the absence of overt mesangial cellproduction could be seen after VEGF treatment in
hyperplasia, our findings regarding VEGF may be rele-HMCs. When we assayed the effects of VEGF on super-
vant for the understanding of the progression of suchoxide production by HMCs, no detectable differences
diseases. In 1996, Shulman et al examined the expressionwere found from untreated cells. These results make it
of VEGF in renal disease. Examination of 47 renal biop-unlikely that the PKC/superoxide pathway is involved
sies from patients with a variety of glomerular diseasesin the actions of VEGF in HMCs. Further studies are
revealed that epithelial expression of VEGF was reducedrequired to assess which tyrosine kinase pathways, such
in many of the biopsies compared with normal glomeruli;as those involving Shc proteins leading to Ras/Raf activa-
however, this decrease was more marked in glomerulition, are involved in the observed actions of VEGF. It is
with disrupted architecture and advanced disease [7].also of interest why VEGF-induced activation of MAPK
and tyrosine kinase pathways leads to mitogenesis in Stronger expression of VEGF was seen in normal glo-
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fonyl fluoride; RT-PCR, reverse transcription-polymerase chain reac-meruli and glomeruli in minimal change disease. Exami-
tion; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electro-
nation of VEGF expression in renal vascular disease and phoresis; TCA, trichloroacetic acid; VAS, vasculotropin; VEGF,
vascular endothelial growth factor; VPF, vascular permeability factor.renal allografts revealed that in glomeruli with segmental
sclerosis (caused by diabetes, nephrosclerosis, or chronic
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